Oral cancer chemotherapy: The critical interplay between patient education and patient safety

Current Oncology Reports

Volumn 12, Issue 4, 2010, Pages 247-252

  Halfdanarson, Thorvardur R ^a   Jatoi, Aminah ^b  

^a UNIVERSITY OF IOWA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Capecitabine; Education; Oral chemotherapy; Safety; Side effects; Temozolomide

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; FLUOROURACIL; GEFITINIB; IMATINIB; LAPATINIB; PACLITAXEL; TAMOXIFEN; TEMOZOLOMIDE; WARFARIN;

ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CHRONIC MYELOID LEUKEMIA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COLON CANCER; DOSAGE SCHEDULE COMPARISON; DOSE CALCULATION; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG TOLERABILITY; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL HEMORRHAGE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; PATIENT AUTONOMY; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT EDUCATION; PATIENT SAFETY; PRACTICE GUIDELINE; PREDICTION; REVIEW; THYROID DISEASE;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PATIENT COMPLIANCE; PATIENT EDUCATION AS TOPIC; SELF ADMINISTRATION;

EID: 77956395390     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-010-0103-6     Document Type: Review

References (23)

1. http://www.jamesgeary.com/blog/aphorisms-by-zoran-t-popovic/ Accessed April 15, 2010.
2. Weingart SN, Brown E, Bach PB, et al.: NCCN task force report: Oral chemotherapy. J Natl Compr Canc Netw 2008, Suppl 3:S1-S14.
3. Winkeljohn DL: Oral chemotherapy medications: The need for the nurse's touch. Clin J Oncol Nurs 2007, 11:793-796.
4. Gornas M, Szczylik C: Oral treatment of metastatic breast cancer with capecitabine: What influences the decision making process? Eur J Cancer Care (Engl) 2010, 19:131-136.
5. Liu G, Franssen E, Fitch MI, Warner E: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997, 15:110-115.
6. Twelves C, Wong A, Nowacki MP, et al.: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005, 352:2696-2704.
7. O'Bryant CL, Crandell BC: Community pharmacists' knowledge of and attitudes toward oral chemotherapy. J Am Pharm Assoc 2008, 48:632-639.
8. Shah HR, Ledbetter L, Diasio R, Saif MW: A retrospective study of coagulation abnormalities in patients receiving concomitant capecitabine and warfarin. Clin Colorectal Cancer 2006, 5:354-358.
9. Catania C, Didier F, Leon ME, et al.: Perception that oral anticancer treatments are less efficacious: Development of a questionnaire to assess the possible prejudices of patients with cancer. Breast Cancer Res Treat 2005, 92:265-272.
10. Eckardt JR, von Pawel J, Pujol JL, et al.: Phase III study of oral compared with intravenous topotecan as second-line therapy in small cell lung cancer. J Clin Oncol 2007, 25:2086-2092.
11. Boogaerts MA, Van Hoof A, Catovsky D, et al.: Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. J Clin Oncol 2001, 19:4252-4258.
12. Mok TS, Wu YL, Thongprasert S, et al.: Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957. This article represents a robust, comparative study that shows an oral cancer agent demonstrated superior outcomes in a select group of cancer patients.
13. Pavlovsky C, Kantarjian H, Cortes JE: First-line therapy for chronic myeloid leukemia: Past, present, and future. Am J Hematol 2009, 84:287-293.
14. Decker V, Spoelstra S, Miezo E, et al.: A pilot study of an automated voice response system and nursing intervention to monitor adherent to oral chemotherapy agents. Cancer Nurs 2009, 32:E20-E29.
15. Grunfeld EA, Hunter MS, Sikka P, Mittal S: Adherence beliefs among breast cancer patients taking tamoxifen. Patient Educ Couns 2005, 59:97-102.
16. Ziller V, KAlder M, Albert US, et al.: Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 2009, 20:431-436.
17. McCowan C, Shearer J, Donnan PT, et al.: Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 2008, 99:1763-1768. This study shows that medication adherence is associated with important clinical outcomes-in this instance, survival outcomes.
18. Machado M, Bajcar J, Guzzo GC, Einarson TR: Sensitivity of patient outcomes to pharmacist interventions. Ann Pharmacother 2007, 41:1770-1781.
19. Reigner B, Verweij J, Dirix L, et al.: Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res 1998, 4:941-948.
20. Koch KM, Reddy NJ, Cohen RB, et al.: Effects of food on the relative bioavailability of lapatinib in cancer patients. J Clin Oncol 2009, 27:1191-1196. The food effects observed in this study are great, thus emphasizing the importance of educating all patients on how best to take oral chemotherapy with respect to food intake.
21. Buzdar AU, Hortobagyi GN, FRye D, et al.: Bioequivalence of 20 mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer. J Clin Oncol 1994, 12:50-54.
22. Jacobson JO, Polovich M, McNiff KK, et al.: American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards. J Clin Oncol 2009, 27:5469-5475. At present, this article constitutes the reference for safe chemotherapy prescribing practices.
23. Weingart SN: Oral chemotherapy safety practices at US cancer centers: Questionnaire survey. BMJ 2007, 334:407.